10 Reasons Illumina's Momentum Is Just Cranking Up
Illumina (NASDAQ: ILMN) knocked the ball out of the park with its second-quarter earnings results. Shares soared after the gene-sequencing pioneer blew away expectations for revenue and earnings. Demand for Illumina's new NovaSeq sequencing system was much stronger than anyone anticipated.
The company's executives discussed its second-quarter performance with analysts after the market closed on Tuesday. Based on the information they provided, I suspect that Illumina's momentum is just cranking up. Here are 10 reasons why. (Quotes courtesy of S&P Global Market Intelligence.)
Image source: Getty Images.
Source: Fool.com